SS-31

Phase 3 Clinical Trials (Barth Syndrome)

Also known as: Elamipretide, Bendavia, MTP-131

Longevity / Anti-AgingSubcutaneousIntravenous

A mitochondria-targeted tetrapeptide that concentrates 1000x in the inner mitochondrial membrane. Restores bioenergetics and reduces oxidative damage.

Molecular Weight640.8 Da

Half-Life (t½)~4 hours

SequenceD-Arg-Dmt-Lys-Phe-NH2

Mechanism of Action

Selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing electron transport chain complexes, reducing ROS production, and optimizing ATP synthesis.

Dosing Protocol

0.25 mg/kg/hr IV infusion or 40mg subcutaneous daily in clinical trials.

Open peptide calculator

Reconstitution

Research-grade: typically supplied in solution.

Storage

Refrigerate 2-8°C. Protect from light.

Side Effects

●Injection site reactions
●Headache
●Generally well-tolerated in trials

Key Research Findings

●Improved cardiac function in Barth Syndrome patients (Phase 3)
●Reversed age-related mitochondrial dysfunction in preclinical models
●Improved exercise tolerance in heart failure trials

Latest Verified Lab Report

No lab reports available for SS-31 yet.

Community-funded testing results will appear here.

Vendor Trust Leaderboard

For SS-31

Trust leaderboard coming soon.

Vendor rankings based on verified lab test results.

Active Deals

Gen Peptide

10% OFF

Shop Vendor